Anne Beal, MD, MPH Joins Omada Health Board of Directors
Dr. Beal brings extensive experience in clinical innovation, patient advocacy, and population health to Omada’s Board.
Read Article
Dr. Beal brings extensive experience in clinical innovation, patient advocacy, and population health to Omada’s Board.
Read Article
With its checkered past and at times questioned clinical merits, BMI’s ubiquity in modern healthcare should be carefully considered.
Read Resource
This insightful webinar delves into the expanding role of GLP-1 medications in treating a wide range of chronic conditions beyond diabetes and obesity.
Watch Video
Error - something went wrong!
Become an Omada Insider, subscribe to our monthly newsletter
Thank you!
New board members provide deep clinical and commercial experience.
Read Article
Omada drills into emerging details of the GLP-1 experience, including compounded GLP-1s, how to manage the drug’s impact on body composition, & ways to assess the value of virtual companion programs.
Read Article
Q&A with Terry Miller, VP of Machine Learning, AI and Data Science Strategy
Read Article
Economic Savings Model for Omada’s Cardiometabolic Programs
Read Article
With the emergence of GLP-1s, there is a divide between patient perception of the medication and how clinical science views it. Find out more with Omada.
Read Article
How Data Science and AI learnings surprised us, taught us, and propelled us forward.
Read Article
Omada delivers GLP-1 FAQs focusing on weight loss quantity vs. quality with timely data and insights for employers, health plans and benefit consultants.
Read Article
Can everyone improve their health? At Omada Health, we believe that with long-term behavior change, the answer is a resounding yes. In the context of organizational health, that...
Read Article
In recent years, diabetes has been on the rise worldwide, causing what’s known as the global "diabetes epidemic." In the U.S., alone, we’ve seen diabetes have significant health and economic consequen
Read Article
Clinical and cultural conversations around obesity have long revolved around BMI (and its credibility), harmful stereotypes, issues of equity and the multi-million dollar weight loss industry.
Read Resource
A side-effect of taking GLP-1s is a loss of muscle mass. Julie Mulcahy, PT, DPT, CAPP OB explores how to combat this with resistance exercises.
Read Article
Lisa McCormick, FNP-BC, RD, CDCES explores the science behind dieting and why it doesn't work. Find out more about sustainable weight loss!
Read Article
Become an Omada Insider, subscribe to our monthly newsletter.
Sign me upOmada Health, the virtual-first healthcare provider, published its 28th peer-reviewed study demonstrating the long-term outcomes of utilizing a behavior change program for members with type 2 diabetes
Read Article
Findings show that meaningfully engaged Omada members on GLP-1s achieved an average of 1.7 times greater weight loss, and inform a new collaboration with Evernorth's EncircleRx program.
Read Article
Join Us at HLTH 2024 in Las Vegas!
Read Article
Charting New Frontiers at the Lockton People Solutions Conference 2024
Read Article
Building on more than a decade of insights and 28 peer-reviewed publications, Omada announces plans to develop more learnings focused on the long-term outcomes of GLP-1s on weight health
Read Article
Loading More...